Crossmark

BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target

Crossref DOI link: https://doi.org/10.1038/s41434-024-00488-4

Published Online: 2024-09-21

Published Print: 2024-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Qiang, Jing

Zhao, Cheng

Shi, Liu-Qing

Sun, Si-Rui

Wang, Hua-Kai

Liu, Shi-Lei

Yang, Zi-Yi

Dong, Ping

Xiang, Shan-Shan

Wang, Jian-Dong

Shu, Yi-Jun https://orcid.org/0000-0001-5235-6154
License Information

Text and Data Mining valid from 2024-09-21

Version of Record valid from 2024-09-21
More Information

Article History

Received: 26 February 2024

Revised: 3 September 2024

Accepted: 13 September 2024

First Online: 21 September 2024

Competing interests

: The authors declare no competing interests.

: Animal experiments involving nude mice met the requirements and were approved by Xinhua Hospital of Shanghai Jiao Tong University School of Medicine (Animal experiment approval number: XHEC–NSFC–2021-093, approval date: February 24, 2021). The study was approved by the Ethics Committee of Xinhua Hospital, Shanghai Jiaotong University School of Medicine. Informed consent was obtained from the patients for this study.

: All authors have seen and approved the manuscript and consent publication.

Document is current

Any future updates will be listed below